Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177 Labeled 6A10 Fab-fragments in Glioblastoma
NCT05533242Phase 1Terminated
- Sponsor
- Universitätsklinikum Münster
- Start
- Jan 2024
- Primary completion
- Sep 2026
- Modality
- Alpha Emitters, Beta Emitters
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [177Lu]Lu-6A10-Fab in glioblastoma (GBM), sponsored by Universitätsklinikum Münster. Primary endpoints: Maximum Tolerated Dose at 1.5 years and Safety of the adjuvant radio-immunotherapy at 1.5 years. Started Jan 2024; status: terminated.
02
Drugs
[177Lu]Lu-6A10-Fab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05533242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533242.